Page 311 - Read Online

Page 16 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58

org/10.20517/2394-4722.2020.58
106. Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell
self-renewal and chemoresistance. Cell Metab 2018;27:136-50.e5.
107. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.
Neoplasia (United States) 2013;15:848-62.
108. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, et al. JAK kinase inhibition abrogates STAT3 activation and head and neck
squamous cell carcinoma tumor growth. Neoplasia 2015;17:256-64.
109. Wen W, Wu J, Liu L, Tian Y, Buettner R, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways
in human ovarian cancer. Mol Cancer 2015;14:100.
110. Plimack ER, LoRusso PM, McCoon P, Tang W, Krebs AD, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.
Oncologist 2013;18:819-20.
111. Su Q, Banks E, Bebernitz G, Bell K, Borenstein CF, et al. Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]
pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus Kinase 1 (JAK1)
inhibitor. J Med Chem 2020;63:4517-27.
112. Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, et al. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and
in combination in vitro and in vivo. Ann Hematol 2019;98:691-703.
113. Stubbs MC, Burn TC, Sparks R, Maduskuie T, Diamond S, et al. The novel bromodomain and extraterminal domain inhibitor
INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin Cancer Res 2019;25:300-11.
114. Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, et al. A phase Ib/II study of the JAK1 inhibitor, itacitinib, plus nab -paclitaxel and
gemcitabine in advanced solid tumors. Oncologist 2019;24:14.
115. Xu L, Feng J, Gao G, Tang H. Momelotinib for the treatment of myelofibrosis. Expert Opin Pharmacother 2019;20:1943-51.
116. Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic
Med Chem Lett 2009;19:5887-92.
117. Chan E, Luwor R, Burns C, Kannourakis G, Findlay JK, et al. Momelotinib decreased cancer stem cell associated tumor burden and
prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget 2018;9:16599-618.
118. Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, et al. Targeted disruption of the JAK2/STAT3 pathway in combination with
systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front Oncol
2014;4:75.
119. Liu T, Li A, Xu Y, Xin Y. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3
inhibition. Oncol Rep 2019;41:1883-92.
120. Giordano G, Parcesepe P, D’Andrea MR, Coppola L, Di Raimo T, et al. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6
complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. J Exp Clin Cancer Res 2019;38:28.
121. Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, et al. Simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib
in janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35:3844-50.
122. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor,
combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest
New Drugs 2019;37:159-65.
123. Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, et al. Phase 1B study of momelotinib combined with trametinib in metastatic,
kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung cancer after platinum-based chemotherapy treatment failure.
Clin Lung Cancer 2018;19:e853-9.
124. Padda S, Reckamp K, Koczywas M, Neal J, Kawashima J, et al. P2.03-043 a phase 1b study of erlotinib and momelotinib for TKI-Naïve
EGFR-mutated metastatic non-small cell lung cancer. J Thorac Oncol 2017;12:S2143-4.
125. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with
myelofibrosis: a randomized clinical trial. JAMA Oncol 2018;4:652-9.
126. Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3
inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 2016;9:137.
127. Jensen KV, Cseh O, Aman A, Weiss S, Luchman HA. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM
brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
PLoS One 2017;12:e0189670.
128. Chuang HY, Su Y, Liu HW, Chen CH, Chiu SC, et al. Preclinical evidence of STAT3 inhibitor pacritinib overcoming temozolomide
resistance via downregulating miR-21-enriched exosomes from M2 glioblastoma-associated macrophages. J Clin Med 2019;8:959.
129. Jensen KV, Hao X, Aman A, Luchman HA, Weiss S. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3
pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neuro-Oncology Adv 2020;2:vdaa020.
130. Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepatic Oncol 2020;7:HEP18.
131. Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, et al. Pacritinib to inhibit JAK/STAT signaling in refractory metastatic
colon and rectal cancer. J Gastrointest Oncol 2017;8:985-9.
132. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant
glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44.
133. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, et al. WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute
myelogenous leukemia cells. Cancer Res 2007;67:11291-9.